Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
02 Maio 2023 - 9:15AM
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life
sciences company focused on developing treatments for adult and
pediatric cancers with potential for Orphan Drug Designation, while
also commercializing diagnostics, announces that two abstracts
featuring the Company’s pan-RAS inhibitor program will be included
in the American Society of Clinical Oncology’s (ASCO) 2023 Annual
Meeting Abstract Book. The first abstract shown below was also
accepted as a poster to be presented during the ASCO annual meeting
to be held June 2-6, 2023 in Chicago.
Michael Poirier, Qualigen's Chairman and CEO,
commented, “Our novel pan-RAS inhibitor program continues to gain
recognition in the scientific community, and the upcoming
presentation of data at the ASCO 2023 conference is another
important step representing continued confirmation of our discovery
and development approach in collaboration with the University of
Louisville (UofL) Research Foundation. We remain on track toward
identifying a lead candidate later this year.”
The two abstracts, which can be found in the
ASCO 2023 Annual Meeting Abstract Book include:
Title: Impact of novel
pan-RAS inhibitors on efficacy and resistance to AMG-510 and
MRTX-1133 in pancreatic cancer cell
linesAuthors/Affiliation: Arshad, et. al.
Qualigen, Inc. and University of Louisville
Title: A novel pan-RAS
inhibitor for luminal B breast
cancerAuthors/Affiliation: Arshad, et. al.,
Qualigen, Inc. and University of Louisville
Qualigen’s pan-RAS inhibitor program is a family
of small molecules designed to prevent mutated RAS gene proteins
from binding to their effector proteins. Exclusively in-licensed
from UofL, compounds from this discovery engine have been shown to
impact tumor growth in multiple in vivo models. Qualigen is
evaluating promising compounds generated from this partnership in
various RAS-driven advanced solid tumors such as pancreatic,
breast, colorectal, and lung cancers.
About Qualigen
Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a diversified
life sciences company focused on developing treatments for adult
and pediatric cancer, while also commercializing diagnostics. Our
investigational QN-302 compound is a small molecule selective
transcription inhibitor with strong binding affinity to G4s
prevalent in cancer cells; such binding could, by stabilizing the
G4s against “unwinding,” help inhibit cancer cell proliferation.
The investigational compounds within Qualigen’s family of RAS
oncogene protein-protein interaction inhibitor small molecules are
believed to inhibit or block the binding of mutated RAS genes’
proteins to their effector proteins, thereby leaving the proteins
from the mutated RAS unable to cause further harm. In theory, such
mechanism of action may be effective in the treatment of about one
quarter of all cancers, including certain forms of pancreatic,
colorectal, and lung cancers. Our investigational QN-247 compound
inhibits nucleolin, a key multi-functional regulatory protein that
is overexpressed in cancer cells; QN-247 may thereby be able to
inhibit the cells’ proliferation. QN-247 has shown promise in
preclinical studies for the treatment of acute myeloid leukemia
(AML). In addition to its oncology drug pipeline, Qualigen has an
established diagnostics business which manufactures and distributes
proprietary and highly accurate rapid blood testing systems to
physician offices and small hospitals for the management of
prostate cancer and other diseases and health conditions.
For more information about Qualigen
Therapeutics, Inc., please visit www.qualigeninc.com.
Contact:
Jules AbrahamJQA Partners,
Inc.917-885-7378jabraham@jqapartners.com
Source: Qualigen Therapeutics, Inc.
Qualigen Therapeutics (NASDAQ:QLGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024